Brooks Laboratories Limited (IN:BROOKS)

:BROOKS

BROOKS

Brooks Laboratories Limited

RESEARCH TOOLSreports

Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

1 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹1.91B

Enterprise Value₹1.90B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)10.7

Beta1.64

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.87

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)3.42

Price to Sales (P/S)4.06

P/FCF Ratio-3.45K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving LeverageThe reduction in total debt and improved debt-to-equity, together with a stable equity ratio, strengthens financial flexibility. Lower leverage reduces interest burden and supports capacity to fund operations or targeted investments without immediate external financing, aiding resilience over the next several months.

Revenue RecoveryA clear revenue recovery in 2025 following prior declines, supported by reported revenue growth, suggests demand stabilization or improved commercial execution. Sustained top-line improvement increases the potential to scale fixed costs and supports a more durable path toward profitability over the medium term.

Operating Margin ImprovementImproved EBIT and EBITDA margins indicate better cost control or a higher-margin product mix. These operating-leverage gains enhance the company's ability to convert revenue into cash from core operations if sustained, narrowing the gap to profitability even while net losses persist.

Bears Say

Persistent Net LossesOngoing net losses and negative return on equity erode shareholder value and limit retained earnings available to fund growth. Persistent unprofitability constrains the company's ability to self-finance, increases reliance on external capital, and raises long-term viability concerns unless profitability is restored.

Negative Operating & Free Cash FlowMulti-year negative operating and free cash flow indicates structural cash burn that pressures liquidity. Even with modest 2025 improvement, sustained negative cash generation forces dependence on debt or equity raises, limiting investment capacity and creating ongoing financing risk over the coming months.

Revenue VolatilityMarked revenue volatility complicates forecasting, margin stability, and investment planning. Fluctuating sales imply unstable demand or execution issues, making consistent scale-up harder and increasing the risk that recent improvements prove transitory rather than a durable structural trend.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

7M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.91B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Jun 01, 2026 which is in 33 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on Feb 06, 2026. The company reported ₹1.867 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.867.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹1.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.747%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.